Daniel G. Amen, MD is a board-certified child and adult psychiatrist, brain imaging specialist, and the chief executive officer of The Amen Clinics in Newport Beach and Fairfield, California and Tacoma, Washington. He is a nationally recognized expert in the fields of neuropsychiatry, or the study of the brain and behavior, and attention deficit disorders. Dr. Amen has pioneered the use of brain imaging in clinical psychiatric practice. His clinics have the world's largest database of functional brain scans for neuropsychiatry. Dr. Amen is Assistant Clinical Professor of Psychiatry and Human Behavior in the University of California, Irvine College of Medicine. Dr. Amen did his general psychiatric training at the Walter Reed Army Medical Center in Washington, DC and his child and adolescent psychiatry training at Tripler Army Medical Center in Honolulu, Hawaii. He has won writing and research awards from the American Psychiatric Association, the US Army and the Baltimore-DC Institute for Psychoanalysis. 949-887-8315, docamen@aol.com

Dr. Wouter Koek, of the University of Texas Health Sciences Center at San Antonio, Department of Psychiatry, headed a drug discovery division aimed at identifying novel compounds for the treatment of disorders such as depression, anxiety, and schizophrenia. He has extensive experience with animal models that are used to evidence antidepressant, anxiolytic-, and antipsychotic-like effects. 210-567-5478

Dr. George I. Papakostas is an instructor in psychiatry at Harvard Medical School and clinical assistant in psychiatry in the Department of Psychiatry at Massachusetts General Hospital. He is also a Staff Physician and Psychiatric Consultant for the Neuroendocrine Unit in the Department of Medicine at Massachusetts General Hospital. The focus of Dr. Papakostas' research includes the pharmacotherapy of treatment-resistant major depressive disorder (MDD), the study of biological and clinical predictors/correlates of clinical response to pharmacotherapy of MDD, and the study of neuroendocrine and metabolic issues in MDD, with a particular emphasis on their relevance to clinical improvement during pharmacotherapy. Dr. Papakostas has received numerous regional, national and international research awards from sources including the American College of Neuropsychopharmacology (ACNP), the Collegium Internationale Neuropsychopharmacologium (CINP), the New Clinical Drug Evaluation Unit of the National Institute of Mental Health (NIMH), and the American Foundation for Research Prevention (AFSP). 617-726-6697

ExpertSource cannot guarantee the immediate availability of these experts or their familiarity with this specific issue.

ExpertSource provides academic and industry experts to the media at no charge. Journalists are encouraged to submit queries to ExpertSource when seeking experts on specific subjects. An online registration form is available at http://www.businesswire.com/.